AstraZeneca Announces Innovative New Partnership With Singapore Institutions to Develop Anti-Cancer... (en identified for clinicalscreening in i...)

AstraZeneca Announces Innovative New Partnership With Singapore Institutions to Develop Anti-Cancer Compounds

Date:8/14/2008

en identified for clinical screening in inoperable HCC by the institutions during 2008 and 2009. Further compounds will be made available at a rate of one per year, for the duration of the partnership, which is in place until 2012.

Professor Soo Khee Chee, NCCS Director and Assistant CEO (Research and Education) of SingHealth, said: "NCCS has a very active research programme run by high quality scientists who have produced some significant outcomes in liver cancer research. This collaboration will give our researchers and clinician scientists another opportunity to make a positive contribution that can benefit all cancer patients. Because of our wide patient base, our teams are better exposed and experienced in all types of cancer. Our large base has allowed us to carry out meaningful and effective clinical trials."

Pre-clinical activities are also included in the partnership, under the terms of which the same institutions will be given annual access to up to six novel candidate drugs for appraisal of activity in the mouse in vivo primary HCC explant model.(4)

For both clinical and pre-clinical activities, AstraZeneca retains the option to assume further development and marketing of all drugs made available as part of the partnership deal.

"This partnership with AstraZeneca is testament to the standard and quality of research in Singapore. We will work closely together to develop new anti-cancer therapies for Asian patients through access to some of AstraZeneca's clinical and pre-clinical compounds and world-class training of our researchers at MCRC," said Associate Professor Goh Boon Cher, Senior Consultant, Dept of Haematology-Oncology, National University Hospital.

Notes to Editors:

AstraZeneca

AstraZeneca is a major international healthcare business engaged in research, development, manufacturing and marketing of prescription pharmaceuticals and supplier for healthcare services. AstraZeneca is one of the world's l
'/>"/>

0

GOOD

Page: 1 2 3 4 5 6
Related medicine technology :

1. AstraZeneca Submits an sNDA for SYMBICORT(R) for the Treatment of Asthma in Children as Young as Age Six
2. Phase III Study of Abbotts Investigational TriLipix(TM) in Combination With AstraZenecas CRESTOR(R) Meets Primary Endpoints on Key Lipids
3. AstraZeneca Submits sNDA for NEXIUM(R) I.V. for Peptic Ulcer Bleed Indication
4. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
5. AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines
6. Volcano Announces Participation in SATURN Clinical Trial Sponsored by AstraZeneca
7. AstraZeneca Submits an sNDA for SYMBICORT(R) for COPD Indication
8. AstraZeneca Submits sNDAs for SEROQUEL XR(TM) for the Treatment of Bipolar Mania and Bipolar Depression
9. AstraZeneca Completes Enrollment in First Phase III Study of the Investigational Drug Vandetanib (ZACTIMA)(R) in Non-Small Cell Lung Cancer
10. New Analysis of METEOR Study Demonstrate Effects of AstraZenecas CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease
11. Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination

Post Your Comments:

AstraZeneca Announces Innovative New Partnership With Singapore Institutions to Develop Anti-Cancer...(en identified for clinicalscreening in i...),Health